| Summary: | Objective: To analyze the effect of adjuvant salvia miltiorrhiza and ligustrazine therapy on
renal function, renal blood perfusion as well as connective tissue growth factor (CTGF) and
transforming growth factor (TGF)-β1 content in patients with chronic renal failure. Methods:
80 patients with chronic renal insufficiency treated in our hospital between March 2013 and
March 2016 were selected for study and randomly divided into observation group (n=40)
and control group (n=40). Control group received conventional therapy and observation
group received conventional + adjuvant salvia miltiorrhiza and ligustrazine therapy. After 3
months of treatment, differences in renal function indexes, illness-related indexes, renal blood
perfusion, CTGF and TGF-β1 content, and so on of two groups of patients were determined.
Results: After 3 months of treatment, serum urea nitrogen (BUN), serum creatinine (Scr),
β2 microglobulin (β2-MG), intermedin (IMD), fibroblast growth factor 23 (FGF23),
cystatin C (CysC), CTGF and TGF-β1 content as well as 24 h urine albumin excretion rate
(UAER) level in urine of observation group were significantly lower than those of control
group (P＜0.05) while glomerular filtration rate (GFR) level and serum adiponectin (APN)
content were significantly higher than those of control group (P＜0.05); renal perfusion
parameters renal cortex Tmax (ATc) and medulla Tmax (ATm) levels of observation group
were significantly lower than those of control group while cortex peak intensity change (ΔAc),
medulla peak intensity change (ΔAm) and peak intensity (PI) levels were significantly higher
than those of control group. Conclusions: Adjuvant salvia miltiorrhiza and ligustrazine therapy
can effectively control the overall condition of patients with chronic renal failure, and plays a
positive role in improving renal function and increasing renal blood perfusion.
|
|---|
